Terms: = Pancreatic cancer AND HER1, YOR227W
26 results:
1. Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to her1-positive cell lines.
Forouharmehr A; Nassiri M; Ghovvati Roudsari S; Javadmanesh A
J Cell Physiol; 2020 May; 235(5):4679-4687. PubMed ID: 31663127
[TBL] [Abstract] [Full Text] [Related]
2. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer.
Qing L; Qing W
Minerva Chir; 2018 Oct; 73(5):488-496. PubMed ID: 29397631
[TBL] [Abstract] [Full Text] [Related]
3. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : her1-4 protein expression and prognosis in pancreatic cancer.
Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
[TBL] [Abstract] [Full Text] [Related]
4. The prospect of patritumab for treating non-small cell lung cancer.
Horinouchi H
Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
[TBL] [Abstract] [Full Text] [Related]
5. Profiling of cMET and HER Family Receptor Expression in pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies: Looking at the Soil Before Planting the Seed.
Muckenhuber A; Babitzki G; Thomas M; Hölzlwimmer G; Zajac M; Jesinghaus M; Bergmann F; Werner J; Stenzinger A; Weichert W
Pancreas; 2016 Sep; 45(8):1167-74. PubMed ID: 26825865
[TBL] [Abstract] [Full Text] [Related]
6. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract] [Full Text] [Related]
7. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in pancreatic cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract] [Full Text] [Related]
8. HER family receptor expression and prognosis in pancreatic cancer.
Bittoni A; Mandolesi A; Andrikou K; Santoni M; Alfonsi S; Lanese A; Loretelli C; Pellei C; Piva F; Scarpelli M; Cascinu S
Int J Biol Markers; 2015 Jul; 30(3):e327-32. PubMed ID: 26109364
[TBL] [Abstract] [Full Text] [Related]
9. Dual targeting of her1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E; Azria D; Mollevi C; Guimbaud R; Tubiana-Mathieu N; Smith D; Delord JP; Samalin E; Portales F; Larbouret C; Robert B; Bibeau F; Bleuse JP; Crapez E; Ychou M; Pèlegrin A
Oncotarget; 2015 May; 6(14):12796-808. PubMed ID: 25918250
[TBL] [Abstract] [Full Text] [Related]
10. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
[TBL] [Abstract] [Full Text] [Related]
11. Molecular recognition of HER-1 in whole-blood samples.
Moldoveanu I; Stanciu Gavan C; Stefan-van Staden RI
J Mol Recognit; 2014 Nov; 27(11):653-8. PubMed ID: 25277089
[TBL] [Abstract] [Full Text] [Related]
12. Epidermal growth factor receptor inhibitors: coming of age.
Mahipal A; Kothari N; Gupta S
Cancer Control; 2014 Jan; 21(1):74-9. PubMed ID: 24357745
[TBL] [Abstract] [Full Text] [Related]
13. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract] [Full Text] [Related]
14. [EGFR/her1: a target life].
Viel E; Curtit E; Mansi L; Vignot S
Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
[TBL] [Abstract] [Full Text] [Related]
15. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
[TBL] [Abstract] [Full Text] [Related]
16. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
Mill CP; Gettinger KL; Riese DJ
Exp Cell Res; 2011 Feb; 317(4):392-404. PubMed ID: 21110957
[TBL] [Abstract] [Full Text] [Related]
17. PET imaging of her1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract] [Full Text] [Related]
18. Bioactivity and molecular targets of novel substituted quinolines in murine and human tumor cell lines in vitro.
Perchellet EM; Crow KR; Gakhar G; Nguyen TA; Shi A; Hua DH; Perchellet JP
Int J Oncol; 2010 Mar; 36(3):673-88. PubMed ID: 20126988
[TBL] [Abstract] [Full Text] [Related]
19. HER-family gene amplification and expression in resected pancreatic cancer.
te Velde EA; Franke AC; van Hillegersberg R; Elshof SM; de Weger RW; Borel Rinkes IH; van Diest PJ
Eur J Surg Oncol; 2009 Oct; 35(10):1098-104. PubMed ID: 19304440
[TBL] [Abstract] [Full Text] [Related]
20. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Senderowicz AM; Johnson JR; Sridhara R; Zimmerman P; Justice R; Pazdur R
Oncology (Williston Park); 2007 Dec; 21(14):1696-706; discussion 1706-9, 1712, 1715. PubMed ID: 18247017
[TBL] [Abstract] [Full Text] [Related]
[Next]
